What is BIOMAb EGFR
|Contents:||Nimotuzumab 50mg INjection|
|Packing:||Price per Vial 10ml|
BIOMAb EGFR, a humanized monoclonal antibody falls under a class of cancer treatment option known as targeted therapy.
Targeted cancer therapies interfere with cancer cell growth and division in different ways and at various points during the development, growth, and spread of cancer. They target molecules specific to cancer cells and prevent the cancerous cells from growing, dividing and spreading uncontrollably.
BIOMAb EGFR (Nimotuzumab) is also known by the brand names Theracim, Theraloc, etc., in different countries where it is approved.
BIOMAb EGFR is currently approved for treatment of head and neck cancers in India, Cuba, Argentina, Colombia, Ivory Coast, Gabon, Ukraine, Peru, Vietnam and Sri Lanka; for glioma (pediatric and adult) in Cuba, Argentina, the Philippines, Myanmar, Mexico, Indonesia, Switzerland, Vietnam, Brazil and Ukraine; for nasopharyngeal cancer (a type of head and neck cancer) in China. It has been granted orphan drug status for Glioma in the USA and for Glioma and pancreatic cancer in Europe. A number of clinical trials are being conducted worldwide to evaluate the efficacy of this molecule in various other indications also like lung cancer, pancreatic cancer, cervical cancer etcHow does BIOMAb EGFR work?
BIOMAb EGFR targets the epidermal growth factor receptor (EGFR) present on the cell surface. The binding of certain growth factors to this receptor starts a series of events that are essential for cell growth, differentiation, and survival (both normal and cancerous). In cancerous cells there is an over expression of EGFR leading to uncontrolled cell growth, proliferation, survival and creation of new blood vessels. A very high level of EGFR is seen in many solid tumors and has been associated with poor treatment outcomes. BIOMAb EGFR binds to the site on EGFR where the growth factors are supposed to bind and thus prevents cancer cells from proliferating, making new blood vessels and evading death. BIOMAb EGFR also helps the body''s immune system in recognizing the cancerous cells and fighting against them.Side effects of BIOMAb EGFR?
Based on the experience of thousands of patients, BIOMAb EGFR remains to be the unique monoclonal antibody of its class that has rarely exhibited any severe skin rashes till date.
Studies conducted worldwide prove that BIOMAb EGFR has a very good safety profile. In an Indian study of 92 patients with head and neck cancer, there have not been any incidences of severe skin rashes, hypomagnesaemia (low magnesium count) and other classical EGFR inhibition related side effects.
In over 9,000 patients worldwide and over 3000 patients treated in India, there have rarely been any toxicities which are usually frequently reported with other EGFR targeting agents. The common side effects that have been observed with BIOMAb EGFR® are chills, rigors, nausea and very minor rashes.mahesh medicos is generic medicine wholesaler from india.for more inquiry please mail us or contact us @ our email id/telephone.we are looking for foreign enquiries only.